Belenos Biosciences
New York, US · Founded 2024 · 1 known investors
Find your way into Belenos Biosciences
Sign up to find every way you can get introduced to Belenos Biosciences
- Your email: who you already know at Belenos Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Belenos Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
Founders & leadership





Board


Investors · 1
How we know: OrbiMed's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$48M disclosed across 1 round · 2024
▶$48MraisedJul 2024 · 2 investors · OtherRule 506(b)
- Bo ChenDirector
- Carl GordonDirector
- Tania DimitrovaExecutive Officer
- David WangDirector
- Megan DowExecutive Officer
- StJohn Donnie McGrathExecutive Officer, Director
- Offering amount
- $55M
- Amount sold
- $48M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Belenos Biosciences do?
- Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
- Who founded Belenos Biosciences?
- Belenos Biosciences was founded by Donnie McGrath, Megan Dow, Tania Dimitrova, Glenn Rosen, Donnie McGrath, M.D., M.P.H., Megan Dow, Ph.D., Tania Dimitrova, M.B.A in 2024.
- Who are Belenos Biosciences's investors?
- Belenos Biosciences's investors include OrbiMed.
- How much funding has Belenos Biosciences raised?
- Belenos Biosciences has disclosed $48M raised across 1 round.
- Where is Belenos Biosciences headquartered?
- Belenos Biosciences is headquartered in New York, US.
